Compare INFQ & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFQ | HAE |
|---|---|---|
| Founded | 2007 | 1971 |
| Country | United States | United States |
| Employees | 205 | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2026 | 1996 |
| Metric | INFQ | HAE |
|---|---|---|
| Price | $9.14 | $77.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $20.00 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 14.3M | 750.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $910,373,000.00 |
| Revenue This Year | $25.46 | N/A |
| Revenue Next Year | $25.00 | $5.23 |
| P/E Ratio | ★ N/A | $38.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.52 | $47.32 |
| 52 Week High | $21.28 | $87.32 |
| Indicator | INFQ | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 61.05 |
| Support Level | $8.54 | $71.93 |
| Resistance Level | $12.22 | $80.90 |
| Average True Range (ATR) | 0.91 | 2.53 |
| MACD | -0.35 | -0.12 |
| Stochastic Oscillator | 6.48 | 74.30 |
Infleqtion Inc developing and commercializing quantum technology products as part of a full-stack platform, which currently includes offerings such as quantum sensing, quantum computing, and software. Its quantum-enabled solutions are focused on addressing the world's pressing challenges, with technologies actively deployed across some sectors today, including defense and security, artificial intelligence (AI), energy optimization, space and frontier, materials discovery, and cybersecurity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.